https://www.selleckchem.com/pr....oducts/i-bet-762.htm
Histologic transformation to diffuse large B-cell lymphoma (tDLBCL) occurs in a significant proportion of indolent lymphomas. However, few studies of novel agents inform its management, particularly when relapsed after or refractory (R/R) to prior treatment. We prospectively evaluated ibrutinib monotherapy in pathologically documented patients with R/R tDLBCL in a single-arm study. The primary endpoint was overall response rate. Twenty patients who had received a median of 4 (range, 2-9) prior lines of therapy overall (median, 2.5; ra
Like
Comment
Share
